COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy.

ABSTRACT: There is a high incidence of acute kidney injury with COVID-19 infections. The etiologies of acute kidney injury could be ischemic acute tubular necrosis or a complex process of complement activation leading to thrombotic microangiopathy. We present a case of 32-year-old Hispanic male with a history of heart transplant, admitted with COVID-19 and atypical hemolytic uremic syndrome, which was successfully treated with Eculizumab.

SUBMITTER: Gill J 

PROVIDER: S-EPMC8383924 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature